A Phase 2 Study of the Safety and Effectiveness of SANGUINATE™ in the Treatment of Vaso-Occlusive Crises in the Ambulatory Setting: A Placebo-Controlled, Single-Dose, Single-Blind Study in Adults With Sickle Cell Disease

Trial Profile

A Phase 2 Study of the Safety and Effectiveness of SANGUINATE™ in the Treatment of Vaso-Occlusive Crises in the Ambulatory Setting: A Placebo-Controlled, Single-Dose, Single-Blind Study in Adults With Sickle Cell Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Apr 2017

At a glance

  • Drugs PEG-haemoglobin carbon monoxide (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Prolong Pharmaceuticals
  • Most Recent Events

    • 29 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 29 Nov 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.
    • 14 Jun 2016 Planned End Date changed from 1 Apr 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top